FDA Approves ORKAMBI — Vertex Pharmaceuticals Incorporated

# FDA Approves Vertex Pharmaceuticals' ORKAMBI for Cystic Fibrosis Vertex Pharmaceuticals Incorporated received FDA approval for ORKAMBI (lumacaftor and ivacaftor), marking a significant expansion of the company's cystic fibrosis portfolio and positioning it to capture a larger share of the estimated $5+ billion CF treatment market. The oral combination therapy addresses a previously underserved patient population, potentially driving substantial revenue growth for Vertex and establishing a new standard of care in CF management.